CYMABAY THERAPEUTICS

cymabay-therapeutics-logo

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral s... mall molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenateโ€™s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

#SimilarOrganizations #People #Financial #Website #More

CYMABAY THERAPEUTICS

Social Links:

Industry:
Biopharma Biotechnology Pharmaceutical

Founded:
1991-01-01

Address:
Hayward, California, United States

Country:
United States

Website Url:
http://www.cymabay.com

Total Employee:
51+

Status:
Active

Contact:
5102938800

Email Addresses:
[email protected]

Total Funding:
366.51 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Universal Analytics Domain Not Resolving Apache


Similar Organizations

acer-therapeutics-logo

Acer Therapeutics

Acer Therapeutics focuses on the acquisition, development, and commercialization of therapies for patients with serious rare diseases.

bexion-pharmaceuticals-logo

Bexion Pharmaceuticals

Bexion Pharmaceuticals is a privately-held biotech company focused on the development and commercialization of innovative cures for cancer.

biomarin-pharmaceutical-logo

BioMarin Pharmaceutical

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

castle-creek-biosciences-logo

Castle Creek Biosciences

Castle Creek Biosciences is focused on developing commercializing novel, personalized gene therapies for rare skin disorders.

crispr-therapeutics-logo

CRISPR Therapeutics

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.

cyteir-therapeutics-logo

Cyteir Therapeutics

Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.

athenex-logo

Athenex

Athenex is a biopharmaceutical company that develops and discovers novel therapies for treating cancer and related conditions.

lentigen-logo

Lentigen

Lentigen Corporation is engaged in the development and commercialization of gene delivery technologies for human diseases.

nirogy-therapeutics-logo

Nirogy Therapeutics

Nirogy Therapeutics is focusing on small-molecule drugs that target the solute carrier family of transporter proteins (SLCTs).

parexel-logo

PAREXEL

PAREXEL is a biopharmaceutical services company that focuses on the development and commercialization of new medical therapies worldwide.

bambu-global-logo

Bambu Global

Bambu Global focuses on developing and commercializing breakthrough scientific discoveries.

pliant-therapeutics-logo

Pliant Therapeutics

Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

galectin-therapeutics-logo

Galectin Therapeutics

Galectin Therapeutics uses galectin science and drug development to create new therapies for fibrotic diseases and cancer.

eyepoint-pharmaceuticals-logo

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases.

reata-pharmaceuticals-logo

Reata Pharmaceuticals

Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.

receptos-logo

Receptos

Receptos focuses on the discovery, development and commercialization of various therapeutics for immune disorders.

revive-therapeutics-logo

Revive Therapeutics

Revive Therapeutics is focused on the research, development and commercialization ofnovel therapies and technologies company.

sorrento-therapeutics-logo

Sorrento Therapeutics

Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.

sunshine-biopharma-logo

Sunshine Biopharma

Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.

synta-pharmaceuticals-logo

Synta Pharmaceuticals

Synta Pharmaceuticals is focused on developing and commercializing small molecule drugs to treat cancer and chronic inflammatory diseases.

targimmune-therapeutics-logo

TargImmune Therapeutics

TargImmune Therapeutics is focused on drug development using novel targeted onco-immunotherapies.

uluru-logo

ULURU

ULURU engages in the research, development, and commercialization of wound care and mucoadhesive film products.


Current Advisors List

eric-converse_image

Eric Converse Board of Directors @ CymaBay Therapeutics
Board_member

kurt-von-emster_image

Kurt von Emster Board of Directors @ CymaBay Therapeutics
Board_member

robert-wills_image

Robert Wills Chairman of the Board @ CymaBay Therapeutics
Board_member
2015-10-01

ed-penhoet_image

Ed Penhoet Board of Directors @ CymaBay Therapeutics
Board_member

louis-lange_image

Louis Lange Member of the Board of Directors @ CymaBay Therapeutics
Board_member

kurt-von-emster_image

Kurt von Emster Board of Directors @ CymaBay Therapeutics
Board_member
2009-01-01

anthony-evnin_image

Anthony Evnin Board of Directors @ CymaBay Therapeutics
Board_member

carl-goldfischer_image

Carl Goldfischer Board of Directors @ CymaBay Therapeutics
Board_member

Current Employees Featured

charles-a-mcwherter_image

Charles A. McWherter
Charles A. McWherter SVP & Chief Scientific Officer @ CymaBay Therapeutics
SVP & Chief Scientific Officer
2007-07-01

becki-filice_image

Becki Filice
Becki Filice Senior Vice President, Portfolio and Product Leadership @ CymaBay Therapeutics
Senior Vice President, Portfolio and Product Leadership
2020-11-01

alexandra-steinberg_image

Alexandra Steinberg
Alexandra Steinberg Senior Medical Director @ CymaBay Therapeutics
Senior Medical Director
2020-01-01

not_available_image

Mary Jean Stempien
Mary Jean Stempien Acting Chief Medical Officer @ CymaBay Therapeutics
Acting Chief Medical Officer

ken-boehm_image

Ken Boehm
Ken Boehm Senior Vice President Human Resources @ CymaBay Therapeutics
Senior Vice President Human Resources
2020-01-01

jeff-stebbins_image

Jeff Stebbins
Jeff Stebbins Senior Director of Research Operations and Scientific Affairs @ CymaBay Therapeutics
Senior Director of Research Operations and Scientific Affairs
2018-01-01

dennis-kim_image

Dennis Kim
Dennis Kim Chief Medical Officer @ CymaBay Therapeutics
Chief Medical Officer

mary-standen_image

Mary Standen
Mary Standen Head of Medical Affairs and Vice President @ CymaBay Therapeutics
Head of Medical Affairs and Vice President
2018-07-01

sujal-shah_image

Sujal Shah
Sujal Shah President and Chief Executive Officer @ CymaBay Therapeutics
President and Chief Executive Officer
2017-04-01

klara-dickinson_image

Klara Dickinson
Klara Dickinson Chief Regulatory and Compliance Officer @ CymaBay Therapeutics
Chief Regulatory and Compliance Officer
2019-01-01

Founder


sujal-shah_image

Sujal Shah

Stock Details


Company's stock symbol is NASDAQ:CBAY

Investors List

abingworth-management_image

Abingworth

Abingworth investment in Post-IPO Debt - CymaBay Therapeutics

silicon-valley-bank_image

Silicon Valley Bank

Silicon Valley Bank investment in Debt Financing - CymaBay Therapeutics

oxford-finance-corporation_image

Oxford Finance LLC

Oxford Finance LLC investment in Debt Financing - CymaBay Therapeutics

merlin-biomed_image

Merlin Biomed

Merlin Biomed investment in Series E - CymaBay Therapeutics

birchmere-ventures_image

Birchmere Ventures

Birchmere Ventures investment in Series E - CymaBay Therapeutics

alta-partners_image

Alta Partners

Alta Partners investment in Series E - CymaBay Therapeutics

kbc_image

KBC

KBC investment in Series E - CymaBay Therapeutics

bay-city-capital_image

Bay City Capital

Bay City Capital investment in Series E - CymaBay Therapeutics

next-chapter-holdings_image

Next Chapter Holdings

Next Chapter Holdings investment in Series E - CymaBay Therapeutics

versant-ventures_image

Versant Ventures

Versant Ventures investment in Series E - CymaBay Therapeutics

Official Site Inspections

http://www.cymabay.com Semrush global rank: 3.02 M Semrush visits lastest month: 5.37 K

  • Host name: 40.70.27.35
  • IP address: 40.70.27.35
  • Location: Boydton United States
  • Latitude: 36.6534
  • Longitude: -78.375
  • Metro Code: 560
  • Timezone: America/New_York
  • Postal: 23917

Loading ...

More informations about "CymaBay Therapeutics"

CymaBay Therapeutics - Crunchbase Company Profile & Funding

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new โ€ฆSee details»

Gilead Sciences Expands Liver Portfolio With Acquisition of โ€ฆ

Feb 12, 2024 FOSTER CITY, Calif. & NEWARK, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a โ€ฆSee details»

Gilead Sciences Announces Completion of Acquisition of CymaBay

On March 22, 2024, Gilead successfully completed the tender offer for all outstanding shares of common stock of CymaBay and accepted for payment all shares validly tendered and not โ€ฆSee details»

Gilead Sciences Announces Completion of Acquisition of CymaBay

Mar 22, 2024 Acquisition Reinforces Gileadโ€™s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the โ€ฆSee details»

CymaBay Therapeutics Company Profile | Management and

CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. ... SQL โ€ฆSee details»

Gilead Sciences Announces Completion of Acquisition of CymaBay

FOSTER CITY, Calif., March 22, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, โ€ฆSee details»

CymaBay Therapeutics Company Profile 2024: Valuation, Investors ...

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases with high unmet medical need. Its โ€ฆSee details»

Gilead Sciences acquires CymaBay Therapeutics - Crunchbase

Feb 12, 2024 CymaBay Therapeutics CymaBay Therapeutics is focused on the development and commercialization of proprietary new medicines for critical human diseases. Acquiring โ€ฆSee details»

CymaBay Therapeutics - Contacts, Employees, Board Members

Organization. CymaBay Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Number of Board Member and Advisor โ€ฆSee details»

Gilead Sciences Acquires CymaBay for $4.3 billion ... - GeneOnline โ€ฆ

Feb 15, 2024 Gilead Sciences, Inc. announced on February 12 that they have agreed to acquire CymaBay for $4.3 billion.CymaBayโ€™s leading drug candidate, seladelpar, used for the โ€ฆSee details»

CymaBay Therapeutics Information - RocketReach

The SIC codes for CymaBay Therapeutics are [28, 283]. Top CymaBay Therapeutics Employees Charles McWherter Chief Scientific Officer at CymaBay Therapeutics United States View. 4 โ€ฆSee details»

CymaBay Therapeutics - Company Profile - Tracxn

Nov 18, 2024 CymaBay Therapeutics ranks 10th among 110 active competitors. 32 of its competitors are funded while 29 have exited. Overall, CymaBay Therapeutics and its โ€ฆSee details»

CymaBay Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap

Explore CymaBay Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 22 clinical trials, 162 news, and 8 literature, Technology Platform:Unknown, Small molecule โ€ฆSee details»

CymaBay Therapeutics - Craft

Mar 25, 2024 CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare โ€ฆSee details»

Mission, Vision & Core Values of CymaBay Therapeutics

Oct 16, 2024 CymaBay Therapeutics is a pharmaceutical company dedicated to improving the lives of patients through innovative therapies. Our mission is to develop novel treatments that โ€ฆSee details»

CymaBay Therapeutics - Funding, Financials, Valuation & Investors

CymaBay Therapeutics is focused on the development and commercialization of proprietary new medicines for critical human diseases. Search Crunchbase. ... How much funding has this โ€ฆSee details»

A Brief History of CymaBay Therapeutics โ€“ CBM

Oct 16, 2024 Founding and Origins of CymaBay. CymaBay Therapeutics was founded in [insert founding year] with the vision of developing innovative medicines to address critical human โ€ฆSee details»

How Does CymaBay Therapeutics Work? โ€“ CBM

Oct 16, 2024 CymaBay Therapeutics strategically files patents to cover various aspects of its drug candidates, including their chemical compositions, methods of use, and formulations. โ€ฆSee details»

Working at CymaBay Therapeutics - Zippia

Learn about working at CymaBay Therapeutics from employee reviews and detailed data on culture, salaries, demographics, management, financial, and more. ... Organization Type. โ€ฆSee details»

CymaBay - Abingworth LLP

CymaBay is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of โ€ฆSee details»

linkstock.net © 2022. All rights reserved